Bliss GVS Pharma Ltd (BLISSGVS) is currently trading at 686.35 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.

Bliss GVS Pharma Limited is a pharmaceutical company engaged in the global manufacturing, marketing, and export of pharmaceutical products, specializing in suppositories and pessaries. The company holds a robust portfolio of over 250 products and operates five WHO-GMP, EU-GMP compliant facilities, with a significant market presence in Sub-Saharan Africa. Bliss GVS focuses on research and development, with a dedicated center and a team of over 50 scientists recognized by the Government of India for advancements in formulations. Despite facing regulatory hurdles in Ghana, the company resolved issues promptly to resume operations and maintain growth momentum. Significant divestments have been made to streamline focus on core pharmaceutical operations, and a new multi-dosage facility in Maharashtra supports expanded product offerings.

Over the past 52 weeks, Bliss GVS Pharma Ltd has traded between a low of ₹118.35 and a high of ₹733.75. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.

Bliss GVS Pharma Ltd has a market capitalization of approximately 7,681.84. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.

Bliss GVS Pharma Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 54.20 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.

Based on its market capitalization of 7,681.84 Cr, Bliss GVS Pharma Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.

Bliss GVS Pharma Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.

The Price-to-Earnings (PE) ratio of Bliss GVS Pharma Ltd is 54.20. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.

The offer price disclosed is ₹299.00 per equity share.

The summary section states consolidated net profit rose 83% YoY to ₹5.14 crore (₹513.72 lakh) for the quarter ended June 30, 2026.

The open offer price is ₹299.00 per equity share, as stated in the Draft Letter of Offer filed with SEBI.

The open offer is at ₹299 per share for up to 2,77,26,848 shares, representing 26.00% of Bliss GVS Pharma’s expanded voting share capital.